| [1] |
GUO Zhiyu, CAO Tianyu, WANG Weidong, GUO Xingxian, MA Wanqi, LU Yuanyuan, ZHAO Xiaodi, JI Gang.
Correlation between blood lipid levels and survival prognosis of gastric cancer patients under operation: A retrospective cohort study
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 687-693.
|
| [2] |
XUAN Wenzhen, GONG Jianmin, LI Na.
Incidence,mortality,and disease burden of cervical cancer in China,1990—2021: trends over the past 30 years and future prediction
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 694-700.
|
| [3] |
LU Tingting, SHI Lijun, LIU Yingzhao, LIANG Huiting, WANG Qi.
Down⁃regulation of α2⁃macroglobulin expression activates TGF⁃β/SMADs signaling pathway to induce cisplatin resistance in ovarian cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 707-714.
|
| [4] |
LI Siyuan, ZHANG Yan, ZHANG Lu.
Application and challenge of CAR-T cell therapy in autoimmune diseases
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 516-524.
|
| [5] |
XIAO Wanting, ZHANG Chunyan, TIAN Biao, GAO Yaya, GAO Guangxun.
A novel immunotherapy strategy for relapsed/refractory multiple myeloma: GPRC5D bispecific antibody
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(4): 399-404.
|
| [6] |
ZHANG Wenhai, LIAN Bin, HOU Qinhan, LIANG Xinguang, YANG Qiujiao, LIANG Ling, CHEN Binjie, WEI Changyuan.
Construction and validation of nomogram model for predicting the relatively long-term survival of metastatic breast cancer based on SEER database
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(4): 454-461.
|
| [7] |
XIE Changquan, HE Fengyi, LU Guodong, LI Qiuyun.
Andrographolide combined with doxorubicin induces cell death in breast cancer cell via ROS-dependent DNA damage
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(3): 302-307.
|
| [8] |
HOU Naiqiao, ZHAI Wei, ZHENG Junhua.
Application status and challenges of artificial intelligence in digital pathology of renal cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(2): 143-151.
|
| [9] |
WANG Yumeng, LIU Zhimin, ZHU Ji, YU Hongping, LI Jie, ZHAO Qing, WU Dawei, SUI Guangyi, ZHOU Ming, YAN Zhao.
Survey and analysis of mutual recognition mechanism for ethical review of clinical trials of tumors in China
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(2): 152-157.
|
| [10] |
NIU Shengli, LIU Bowei.
Effects of high sodium diet on the burden of gastric cancer in Chinese residents and a trend analysis,1990—2019
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(2): 186-192.
|
| [11] |
MA Fuchao, LIU Aiquan, XIE Weishun, SHEN Yanhua, FENG Jie, JIANG Qi, GE Lianying.
Screening and diagnostic efficacy evaluation of risk miRNAs during the development of gastric cancer: a multicenter study
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(2): 193-199.
|
| [12] |
CHEN Lijun, LIANG Xiumei, WU Yun, LU Xiangning, XIE Ganglin, YANG Zhijun.
A survival report of 78,046 patients with malignant tumor from a hospital?based cancer registry database
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(2): 229-237.
|
| [13] |
LONG Yuhao, ZHENG Bohao, ZHOU Shengtao.
Effect of m6A modification on ovarian cancer and its value as a potential therapeutic target
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(2): 238-242.
|
| [14] |
WANG Huilin, JIANG Wei, YU Qitao.
Progress in the application of patient?reported outcomes in tumor immunotherapy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(2): 255-260.
|
| [15] |
ZHOU Xinmeng, LIAO Qingqing, XIE Na, HUANG Canhua, SUN Xiaodong, ZHANG Yuanyuan.
Inventory of tumor protein marker research progress in 2023
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(1): 23-31.
|
